Results 31 to 40 of about 79,614 (239)
Human medicines European public assessment report (EPAR): Jylamvo, methotrexate, Arthritis, Psoriatic,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Psoriasis,Arthritis, Rheumatoid,Arthritis, Date of authorisation: 29/03/2017, Revision: 4, Status: Authorised [PDF]
Case Medical Research, 2019 openalex +2 more sources
International Journal of Laboratory Hematology, Volume 45, Issue 1, Page 53-63, February 2023., 2023 Abstract Introduction Paediatric AML patients with hyperleukocytosis have a poor prognosis and higher early mortality. Therefore, more studies are needed to explore relevant prognostic indicators and develop effective prevention strategies for this type of childhood AML. Methods All original data were obtained from the TARGET database.
Nan Mei +6 more
wiley +1 more source
Khyber Medical University Journal, 2020 OBJECTIVE: To determine the diagnostic importance of immunohistochemistry (IHC) in classifying acute lymphoblastic leukemia (ALL) in a tertiary care center.
Nazish Farooq +3 more
doaj +1 more source
Toll-like Receptors 2, 3, and 4 in Childhood Acute Lymphocytic Leukemia
Revista Brasileira de Cancerologia, 2023 Introduction: Acute lymphocytic leukemia (ALL) is the most common cancer type in children and accounts for 80% of pediatric leukemias. Novel targets are necessary to improve survival rates for refractory and relapsed disease.
Matheus Loureiro da Silva Cruz +11 more
doaj +1 more source
Pediatric-inspired regimen with late intensification and increased dose of L-asparaginase for adult acute lymphoblastic leukemia: the KALLA 1406/1407 study [PDF]
The Korean Journal of Internal Medicine, 2021 Background/Aims The objective of this study was to evaluate the efficacy and feasibility of the pediatric-inspired regimen of the adult acute lymphoblastic leukemia (ALL) Working Party, the Korean Society of Hematology.
Dong Won Baek +7 more
doaj +1 more source
Clinical Pediatric Hematology-Oncology, 2022 B-cell precursor acute lymphoblastic leukemia (BCP-ALL), which is the most common type of ALL, has an excellent prognosis with long-term event-free survival of 90%.
Jianne Lee, Sun Young Kim, Yeon Jung Lim
doaj +1 more source
Novel Markers in Pediatric Acute Lymphoid Leukemia: The Role of ADAM6 in B Cell Leukemia
Frontiers in Cell and Developmental Biology, 2021 BackgroundThe extensive genetic heterogeneity found in the B cell precursor acute lymphoblastic leukemia (BCP-ALL) subtype of childhood ALL represents a potential repository of biomarkers. To explore this potential, we have carried out in silico analysis
Laila Alsuwaidi +3 more
doaj +1 more source
Automated Identification of Cell Populations in Flow Cytometry Data with Transformers [PDF]
Computers in Biology and Medicine, Vol. 144 (2022), 2021 Acute Lymphoblastic Leukemia (ALL) is the most frequent hematologic malignancy in children and adolescents. A strong prognostic factor in ALL is given by the Minimal Residual Disease (MRD), which is a measure for the number of leukemic cells persistent in a patient.
arxiv +1 more source
Chloroma of perianal region masquerading as perianal abscess
Indian Journal of Dermatology, 2013 Chloroma, also called granulocytic sarcoma (GS) or Myeloid Sarcoma, is a rare malignant extra-medullary neoplasm of myeloid precursor cells. It is usually associated with myeloproliferative disorders but its appearance may precede the onset of leukaemia.
Rajeev Sen +5 more
doaj +1 more source
Frontiers in Immunology, 2021 T cells engineered with chimeric antigen receptor (CAR-T cells) are an effective treatment in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma.
Marika Guercio +20 more
doaj +1 more source